NPD in Europe
This article was originally published in The Rose Sheet
Executive Summary
NPD Group has entered into a non-binding letter of intent with TNS Infratest to acquire its Italian perfumery business, company announces Oct. 12. TNS Infratest is an Italian subsidiary of international market information provider Taylor Nelson Sofres. Deal aims to "strengthen NPD's position as the leading provider of comprehensive sales tracking information for the Selective Beauty industry in Europe and the U.S.," according to NPD. "This is an exciting step forward and paves the way for future expansion of our Selective Beauty business in Europe and Asia," NPD Europe President Andy Tarshis notes...
You may also be interested in...
NPD Beauty
Claude Charbit is appointed to newly created position of president, Global Beauty, effective Nov. 1, consumer and retail information company reports Oct. 24. Charbit has been serving as a special adviser to NPD regarding its European Beauty business since July 2003 and recently led NPD negotiations with TNS Infratest to acquire its Italian perfumery business (1"The Rose Sheet" Oct 17. 2005, In Brief). Exec has held positions at Information Resources Inc, SOFRES, EuroRSCG Group and AC Nielsen. Charbit will report to NPD Europe President Andy Tarshis. His experience will be "invaluable" in "continuing to grow our beauty business, leveraging our current position as market leader in France and Italy for continued growth in Europe and beyond," Tarshis said...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.